 |
Neuropsychological Tests (Latest Articles)
Latest indexed articles for 'Neuropsychological Tests'
Articles 141 to 150 of 200:
30 Aug 2009 
BACKGROUND: Neuropsychological deficits in patients with multiple sclerosis (MS) have been shown to be associated with the major pathological substrates of the disease, ie, inflammatory demyelination and neurodegeneration. Double inversion recovery ...
rec_pub_19752305-cortical-lesions-atrophy-associated-cognitive-impairment-relapsing.htm
30 Aug 2009 BACKGROUND: Extrapyramidal signs (EPSs) are commonly accepted as a feature of Alzheimer disease (AD) and may influence both the profile of impairment and prognosis. OBJECTIVE: To examine rates of occurrence and risk factors for all types of EPSs and ...
rec_pub_19752301-extrapyramidal-signs-diagnosis-incident-alzheimer-disease-prospective.htm
Apathy is not associated with basal ganglia atrophy in frontotemporal dementia.
30 Aug 2009 OBJECTIVE: To determine whether basal ganglia atrophy, known to be associated with apathy in nondementia populations, was associated with presence of apathy in patients with frontotemporal dementia (FTD). METHODS: A cross-sectional case study was ...
rec_pub_19700954-apathy-associated-basal-ganglia-atrophy-frontotemporal-dementia.htm
30 Aug 2009 OBJECTIVES: The Revised Cambridge Cognitive Examination (CAMCOG-R) is a cognitive screen that has been used to discriminate individuals with dementia from cognitively intact older people. It consists of items assessing various cognitive domains, but ...
rec_pub_19700951-measuring-impairments-memory-executive-function-older-people-using.htm
30 Aug 2009 OBJECTIVES: To examine the efficacy and tolerability of atomoxetine (ATX) in improving cognitive performance of patients with Alzheimer dementia. DESIGN: A randomized, double-blind, placebo (PLA)-controlled, parallel-groups study, starting with a ...
rec_pub_19700948-atomoxetine-augmentation-cholinesterase-inhibitor-therapy-patients.htm
30 Aug 2009 OBJECTIVES: Agitation/aggression in Alzheimer disease (AD) is a major cause of patient distress, caregiver burden, and institutionalization. Enhanced behavioral responsiveness to central nervous system norepinephrine (NE) release may contribute to ...
rec_pub_19700947-prazosin-treatment-behavioral-symptoms-patients-alzheimer-disease.htm
Brief psychosocial therapy for the treatment of agitation in Alzheimer disease (the CALM-AD trial).
30 Aug 2009 BACKGROUND: Good practice guidelines state that a psychological intervention should usually precede pharmacotherapy, but there are no data evaluating the feasibility of psychological interventions used in this way. METHODS: At the first stage of a ...
rec_pub_19700946-brief-psychosocial-therapy-treatment-agitation-alzheimer-disease-calm.htm
30 Aug 2009 
rec_pub_19673729-returning-pediatric-athletes-play-concussion-evidence-lack-thereof.htm
Brain activation changes before and after PAP treatment in obstructive sleep apnea.
30 Aug 2009 STUDY OBJECTIVES: Obstructive sleep apnea syndrome (OSAS) is associated with cognitive and functional deficits, most of which are corrected after positive airway pressure (PAP) treatment. Previous studies investigating the neural underpinnings of ...
rec_pub_19750921-brain-activation-changes-pap-treatment-obstructive-sleep-apnea.htm
Validation of the revised quick cognitive screening test.
30 Aug 2009 OBJECTIVE: To validate the revised version of the Quick Cognitive Screening Test (QCST). DESIGN: Cross-sectional. SETTING: Senior homes; hospital; college campus. PARTICIPANTS: Participants (N=377; 114 men, 263 women) were recruited comprising ...
rec_pub_19735773-validation-revised-quick-cognitive-screening-test.htm
Results: [1-10] [11-20] [21-30] [31-40] [41-50] [51-60] [61-70] [71-80] [81-90] [91-100] [101-110] [111-120] [121-130] [131-140] [141-150] [151-160] [161-170] [171-180] [181-190] [191-200]